A new survival score for patients with brain metastases from non-small cell lung cancer

Strahlenther Onkol. 2013 Sep;189(9):777-81. doi: 10.1007/s00066-013-0362-x. Epub 2013 Jun 7.


Background and purpose: Non-small cell lung cancer (NSCLC) is the most common primary tumor in patients developing brain metastasis. This study was performed to develop and validate a survival score particularly for this group of patients.

Patients and methods: In this study, the data of 514 patients treated with whole-brain radiotherapy (WBRT) alone for brain metastasis from NSCLC were retrospectively analyzed. The patients were divided into a test group (n = 257) and a validation group (n = 257). In the multivariate analysis of the test group, gender, performance status, and extracranial metastases were independent predictors of survival and, therefore, included in the scoring system. The score for each of the three factors was obtained from the 6-month survival rate (in %) divided by 10. The total scores that represented the sum of the three scores were 5, 8, 9, 11, 12, or 15 points. Three prognostic groups were formed according to the total scores.

Results: The 6-month survival rates in the test group were 9 % for 5-9 points (group A), 54 % for 11-12 points (group B), and 79 % for 15 points (group C). In the validation group the 6-month survival rates were 14, 56, and 78 %, respectively. The comparisons between the prognostic groups A, B, and C of the test and the validation group did not reveal any significant differences.

Conclusion: This new score appears valid and reproducible. It can help predict the survival of patients with brain metastasis from NSCLC.

Publication types

  • Controlled Clinical Trial

MeSH terms

  • Brain Neoplasms / mortality*
  • Brain Neoplasms / radiotherapy
  • Brain Neoplasms / secondary*
  • Carcinoma, Non-Small-Cell Lung / mortality*
  • Carcinoma, Non-Small-Cell Lung / radiotherapy
  • Carcinoma, Non-Small-Cell Lung / secondary*
  • Comorbidity
  • Female
  • Germany / epidemiology
  • Humans
  • Lung Neoplasms / mortality*
  • Lung Neoplasms / therapy
  • Male
  • Middle Aged
  • Prevalence
  • Radiotherapy, Conformal / mortality*
  • Reproducibility of Results
  • Risk Assessment
  • Sensitivity and Specificity
  • Survival Analysis*
  • Survival Rate